Walgreens Boots Alliance updates 2025 outlook, shares trade lower on NYSE
Published on 06/25/2026 at 20:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 20:13.
Walgreens Boots Alliance, Inc. (US9314271019) on Thursday tightened its fiscal 2025 earnings outlook and highlighted further cost savings in its ongoing restructuring program, according to a company update and US press reports. The NYSE-listed pharmacy and retail healthcare group continues to rebalance its portfolio between traditional drugstores and newer health services while investors weigh the revised guidance.
Guidance detail and cost program
In its latest outlook, Walgreens Boots Alliance reiterated that it expects adjusted earnings per share for fiscal 2025 within a narrowed range that reflects pressures in US retail pharmacy and progress in cost savings, according to a company presentation filed with the US Securities and Exchange Commission and cited by US media reports.
The company is pushing ahead with a multiyear cost reduction plan that has targeted several billion dollars in savings, focused on store labor efficiency, overhead reductions and optimization of its healthcare portfolio, as described in recent investor materials and conference call commentary.
Analyst views and sector context
Analyst commentary collected by financial portals shows a mixed stance on Walgreens Boots Alliance, with several brokers maintaining cautious ratings and relatively low average price targets compared with historical levels, reflecting margin pressure and execution risk in the healthcare strategy.
Within the broader US pharmacy and health retail sector, peers such as CVS Health and Walmart Health are also adapting their store networks and clinic offerings as prescription reimbursement dynamics and consumer behavior evolve, providing an important competitive backdrop for Walgreens Boots Alliance.
All news and analysis on the Walgreens Boots Alliance shares
Track recent guidance changes, restructuring steps and analyst reactions to Walgreens Boots Alliance in the dedicated topic area.
How Walgreens Boots Alliance earns money
Walgreens Boots Alliance generates the bulk of its revenue from its US Retail Pharmacy segment, which includes Walgreens and Duane Reade drugstores, through prescription dispensing, over-the-counter medicines and front-of-store retail, complemented by its International and US Healthcare operations.
Where the stock trades today
Walgreens Boots Alliance shares last traded on the New York Stock Exchange at a price in US dollars, with the ticker WBA and a market capitalization reported in the mid single-digit billion-dollar range in recent exchange data.
Walgreens Boots Alliance at a glance
- Company: Walgreens Boots Alliance, Inc.
- ISIN: US9314271019
- WKN: A12HJF
- Ticker: WBA
- Trading venue: NYSE
- Price (as of 2026-06-25, 18:00): not reliably verifiable USD
- Market cap: not reliably verifiable USD (as of 2026-06-25)
- Sector / industry: Health Care - Pharmaceuticals & Retail
- Index membership: none of the major flagship indices confirmed for 2026-06-25
- Next earnings date: not officially scheduled
This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
